Article Per Year (5 Year)
p-Index From 2021 - 2026
0.817
P-Index
This Author published in this journals
All Journal Jurnal Manajemen CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL Journal of Pharmaceutical Care and Sciences Jurnal Sosial dan Sains
Haikal, Vikri
Unknown Affiliation
Astronomy Biochemistry, Genetics & Molecular Biology Chemistry Economics, Econometrics & Finance Environmental Science Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Library & Information Science Medicine & Pharmacology Physics Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review Haikal, Vikri; Soelistijo, Soebagijo Adi; Puspa; Prajitno, Jongky Hendro
Current Internal Medicine Research and Practice Surabaya Journal Vol. 5 No. 1 (2024): CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/cimrj.v5i1.50710

Abstract

Introduction: One of the leading causes of death in patients with diabetes mellitus is Diabetic Kidney Disease (DKD). Canagliflozin is one of the therapeutic options that can be used to mitigate the progression of DKD. However, the limited existing studies have left the data regarding the effects of canagliflozin on the progression of DKD still unclear. Therefore, a comprehensive study on the efficacy and safety of using canagliflozin in patients with DKD is warranted.Methods: We performed a systematic search in the PubMed, Cochrane Library, ResearchGate, and Springer for randomized, placebo-controlled trials of the treatment of type 2 diabetes mellitus (T2DM) with canagliflozin that were published. A total of 25 journals were identified, and after excluding irrelevant studies, eighteen studies were ultimately included in this systematic review with total participants of 20,047.Results: Canagliflozin reduces the rate of estimated glomerular filtration rate (eGFR) decline in patients with diabetes mellitus. The reduction of urinary albumin-to-creatinine ratio (UACR) level was greater in canagliflozin group than in the control group, and the progression of albuminuria was slower in the canagliflozin group than in the control group.Conclusion: The use of Canagliflozin is considered to be one of the effective therapeutic options for kidney protection in patients with diabetes mellitus who are at risk of chronic kidney disease (CKD).
ANALISIS PENGELOLAAN ANGGARAN PENDAPATAN DAN BELANJA DESA SERTA PENERAPAN AKUNTABILITAS DI DESA MLATI MOJO KEDIRI Haikal, Vikri; Hidayati, Amalia Nuril
Jurnal Manajemen Vol. 13 No. 1 (2023): JURNAL MANAJEMEN VOL. 13 NO. 1 JUNI 2023
Publisher : Fakultas Ekonomi Universitas Sarjanawiyata Tamansiswa

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26460/jm.v13i1.3743

Abstract

Anggaran pendapatan dan belanja desa memuat beragam sumber penerimaan dan pengeluaran desa, serta juga harus dibuktian dalam laporan pertanggungjawaban dan informasi yang penting bagi masyarakat desa setempat. Tujuan penelitian ini 1). untuk mengetahui pengelolaan anggaran pendapatan desa dan belanja desa. 2). Hambatan-hambatan dalam penggelolaan anggaran pendapatan dan belanja desa. 3). Untuk mengetahui penerapan akuntabilitas APBdesa di desa Mlati Mojo Kediri. Metode dalam penelitian ini menggunakan pendekatan kualitatif dengan jenis studi kasus. Pengumpulan data dilakukan dengan beberapa tehnik yaitu Observasi, Wawancara, Dokumentasi. Hasil penelitian ini menunjukan 1). Penggelolaan anggaran pendapatan desa dan belanja desa sudah berjalan baik. 2). Hambatan-hambatan dalam penggelolaan anggaran pendapatan dan belanja desa mulai hambatan secara internal maupun hambatan eksternal. 3). Penerapan akuntabilitas APBdesa di desa Mlati Mojo Kediri sudah berjalan baik.
F Formulasi Dan Uji Stabilitas Fisik Body Wash Ekstrak Etanol 70% Bunga Telang (Clitoria ternatea L.): Formulasi Dan Uji Stabilitas Fisik Body Wash Ekstrak Etanol 70% Bunga Telang (Clitoria ternatea L.) Haikal, Vikri; Audina, Mia; Hidayah, Nur; Budi, Setia
Jurnal Pelayanan Kefarmasian dan Sains Vol 4 No 1 (2023): Journal of Pharmaceutical Care and Sciences (JPCS)
Publisher : LPPM Universitas Sari Mulia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33859/jpcs.v4i1.418

Abstract

ABSTRACT Background: Body wash is made by adding antibacterial active ingredients to suppress the growth of microorganisms. Antibacterial metabolite compounds owned by 70% ethanol extract of butterfly pea flowers are saponins, tannins, terpenoids, alkaloids and flavonoids Objective: Knowing the effect of differences in natrosol concentrations of 0.5%, 1% and 1.5% on the stability of body wash formulations of butterfly pea flowers Methods: The research method used is quasy-experimental with a one-group pretest-posttest design Results: The organoleptical stability of the three stable formulas is consistent and has a purplish-blue color, the characteristic smell of falcon flowers. All three stable formulas are homogeneous. The high stability of foam and viscosity of the three formulas are stable and qualified. The pH stability of all three formulas meets the qualifying range. Conclusion: Variations in natrosol concentration affect the stability test of pH evaluation and have no effect on organoleptis stability tests, homogeneity, foam height, viscosity and emulsion type. The most optimal formulation is formulation II (1%)
Neoadjuvant Toripalimab for Renal Cell Carcinoma: A Systematic Review Rananda, Arif; Haikal, Vikri; Oktavian, Puguh; Setyobudi, David; Kristanto, Roy Dwi Antariksa
Jurnal sosial dan sains Vol. 5 No. 11 (2025): Jurnal Sosial dan Sains
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/jurnalsosains.v5i11.32548

Abstract

Toripalimab, a programmed cell death protein-1 (PD-1) inhibitor, has emerged as a promising immunotherapy for renal cell carcinoma (RCC). This systematic review consolidates current evidence on the efficacy and safety of toripalimab-based regimens in RCC management. A systematic review was conducted following PRISMA guidelines and a pre-registered protocol (PROSPERO: CRD42021274404). Multiple databases and trial registries were searched from February 23, 2025. Six studies, including randomized controlled trials (RCTs), case-control studies, and case reports, were included for qualitative synthesis. The analysis demonstrated that toripalimab, particularly in combination with axitinib, significantly improved clinical outcomes compared to standard therapies like sunitinib. One major RCT reported a significant improvement in progression-free survival (PFS) (median 18.0 vs. 9.8 months) and a higher objective response rate (ORR) (56.7% vs. 30.8%). The combination also reduced the risk of disease progression or death by 35% (HR 0.65; 95% CI 0.49–0.86) and showed a significant overall survival (OS) benefit (HR 0.61; 95% CI 0.40–0.92). Favorable responses were also observed in challenging subgroups, including elderly patients and those with sarcomatoid RCC. Adverse events were consistent with known profiles of PD-1 and VEGFR inhibitors, including hypertension, hepatic enzyme elevation, and fatigue, and were generally manageable. Toripalimab-based regimens, especially in combination with axitinib, demonstrate significant improvements in PFS, ORR, and OS for patients with RCC, with a manageable safety profile. These findings support its potential as a valuable therapeutic option. However, further large-scale, multi-center studies with longer follow-up are warranted to confirm these findings.
Co-Authors Amalia Nuril Hidayati Jongky Hendro Prajitno Kristanto, Roy Dwi Antariksa Mia Audina, Mia Nur Hidayah Oktavian, Puguh Puspa Rananda, Arif Setia Budi Setyobudi, David Soelistijo, Soebagijo Adi